Skip to main
  1. Stocks
  2. ResMed
  3. Forecast
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 27%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is supported by a large, underdiagnosed sleep apnea market, with only 20% diagnosis in the US and management believing awareness drivers like GLP-1 prescribing, wearables, and partnerships are bringing more patients into the OSA funnel. Its 1Q27 results showed fundamental strength, with revenue of $1,415m up 5.9% YoY, non-GAAP gross margin of 62.5%, and underlying EPS of $2.91 up 14% YoY, while Americas device growth of 5.5% and Americas mask growth of 10.0% highlighted resilient core demand. The outlook is further underpinned by recurring masks and software revenue, continued market-share gains from product innovation, and strong cash generation that enabled over $1bn of shareholder returns in 1Q27 and guidance for more than $1.85b in FY27.

Bears say

ResMed is facing a negative fundamental setup because foreign exchange is pressuring both profitability and growth, with FX reducing EPS by $0.08 and expected to create a 60 bps revenue headwind in FY27. Cash generation is also weakening, as net operating cash flow fell to $422m in 1Q27 from $457m in 1Q25 and free cash flow declined 10% YoY amid higher inventory and cash tax prepayments, while capex rose to 3.4% of revenue. The downside case assumes a 20–40% fall in devices and masks growth in FY25–26e, and the broader thesis is vulnerable to competitive pressure, weaker healthcare spending, and FDA actions.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 27% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

ResMed (RMD) Analyst Forecast & Price Prediction

Get the latest ResMed (RMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ResMed (RMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Hold consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $250.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $250.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


ResMed (RMD) Analyst Forecast & Price Prediction

Get the latest ResMed (RMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ResMed (RMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RMD stock data and trends